Nonalcoholic fatty liver disease (NAFLD), which has recently undergone a change in its definition and acronym to “metabolic dysfunction associated fatty liver disease (MAFLD),” is clinically significant as an increasingly prevalent independent risk factor for cardiovascular diseases. Insulin resistance is considered to be a key mechanism in the development and progression of NAFLD/MAFLD, and fatty liver disease itself may exacerbate insulin resistance. In this review, we describe the mechanisms underlying the interaction between insulin resistance and fatty liver, and we summarize the therapeutic attempts based on those mechanisms.
Citations
Citations to this article as recorded by
Nonalcoholic fatty liver disease and heart failure with preserved ejection fraction: a focus on risk factors and management Joonpyo Lee, Mi-Seung Shin Cardiovascular Prevention and Pharmacotherapy.2025; 7(1): 1. CrossRef
Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective Inha Jung, Dae-Jeong Koo, Won-Young Lee Diabetes & Metabolism Journal.2024; 48(3): 327. CrossRef
A Comprehensive Review of Pathophysiological Link Between Non-alcoholic Fatty Liver Disease, Insulin Resistance, and Metabolic Syndrome Eudith Januario, Aly Barakat, Abhivanditha Rajsundar, Zahra Fatima, Varda Nanda Palienkar, Arjun V Bullapur, Sunchandandeep Singh Brar, Punam Kharel, Mishal Mohammed Koyappathodi Machingal, Amena Backosh Cureus.2024;[Epub] CrossRef